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Cost-utility analyses however require preference based measures
to calculate quality adjusted life years. This study aimed to
estimate the association between health utility and DLQI
response in patients with chronic plaque psoriasis. METHODS:
A consecutive sample of all patients treated for a primary diag-
nosis of psoriasis at Llandough Hospital, Cardiff, UK over a
period of two years were identiﬁed from the hospital record
system. All patients were sent the Health Outcomes Data Reposi-
tory (HODaR) survey including the EQ-5D and DLQI instru-
ments. Individual patient utility was estimated from EQ-5D
responses using the standard UK scoring algorithm. A predictive
regression model was built to estimate EQ-5D utility scores from
patient DLQI responses. RESULTS: A total of 94 psoriasis
patients responded to the survey. Fifty percent of patients were
female, and the mean age was 50.0 years (range from <10 to >80
years). Patients had been diagnosed with psoriasis for a mean of
15.6 years. Over the previous year 20.4% of patients had at least
one inpatient admission and 66.0% at least one outpatient atten-
dance for their psoriasis. Eighteen patients (19%) reported that
they were currently received treatment with a systemic agent or
with PUVA. The regression model found DLQI score to be sig-
niﬁcantly related to the EQ5D utility score. Estimated utility
at zero DLQI, the best possible response, was 0.956 (standard
error 0.039, p < 0.001) and each one point rise in DLQI was
associated with a decrease of 0.02548 (standard error 0.004,
p < 0.001) in estimated utility. The model described 27% of the
variation in the EQ5D data for the survey respondents.
CONCLUSION: It was possible to estimate utility from patient
DLQI score in a population with psoriasis requiring hospital
management.
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OBJECTIVES: To know the repercussion of the moderate-severe
psoriasis on the health-related quality of life (HRQoL), the
health state utilities, the direct costs and the health resources
employees in the last year. METHODS: An observational (natu-
ralistic) study conducted at Dermatology centres in Spain and
Portugal. A total of 332 dermatologists included 10 consecu-
tive patients with moderate to severe psoriasis. The case report
form includes information about the Psoriasis Disability Index
(PDI), as well as variables of severity: Body surface area (BSA)
and Psoriasis Area and Severity Index (PASI). Health state utili-
ties were assessing by the Time Trade-off and Willingness to pay
methods. Data collected also include the direct cost in treatments
and days of sick leave, number of medical visits, hospitalization
days and emergency visits in the last year. RESULTS: 3320
patients were assessed. Mean BSA involvement was 23% (95%
CI: 22.2–23.3%) and mean PASI score was 14.3 (95% CI: 13.9–
14.6%). The mean value of the PDI was 8.93 (IC95% 7.83–
9.21). There was a consistent decrease in HRQoL with increase
in disease severity. The mean amount of remaining life that
patients were willing to sacriﬁce to be free from psoriasis was 25
months (95% CI: 23.4–26.8) and the mean proportion of
monthly income that were willing to pay was 29% (95% CI:
28.1–30.1), with the amount of time or income increasing with
disease severity. In 89% of patients, psoriasis represented a mean
direct treatment expense of 816 € yearly. CONCLUSION: The
psoriasis causes a negative impact in the HRQoL and in the
patient’s budget. This study establish a relationship between
the severity of psoriasis and the amount of money or time of
remaining life that patients are willing to pay or sacriﬁce, respec-
tively, to be free of psoriasis.
PSK13
PSYCHOMETRICVALIDATION OFTHE OILY SKIN SELF
ASSESSMENT SCALE (OSSAS) ANDTHE OILY SKIN IMPACT
SCALE (OSIS)
Arbuckle R1, Clark M2, Scott J3, Harness J4, Bonner N1, Draelos Z5,
Rizer R6
1Mapi Values Ltd, Bollington, Cheshire, UK, 2Pﬁzer Inc, Ann Arbor, MI,
USA, 3Mapi Values Ltd, Boston, MA, USA, 4Pﬁzer Global R&D, Ann
Arbor, MI, USA, 5Wake Forest University School of Medicine, High
Point, NC, USA, 6Thomas J Stephens & Associates Inc, Colorado
Springs, CO, USA
OBJECTIVES: The OSSAS and OSIS are patient reported
outcome measures developed using focus groups to assess facial
Oily Skin (OS) severity and the psychosocial impact of oily skin,
respectively. This study examines the validity and reliability of
these measures in a cross-sectional study. METHODS: The
OSSAS, OSIS and concurrent measures (Skindex and AcneQoL)
were administered to 202 OS patients at seven sites across the
USA. A sub-group of 152 patients returned 1–2 weeks later for
test-retest reliability evaluation. RESULTS: Of the 202 partici-
pants, 72.8% were female; 64.4% had acne in addition to OS.
Item reduction analyses resulted in a 14 item OSSAS with ‘Sen-
sations’ (5 items), ‘Tactile’ (3 items) and ‘Visual’ (4 items)
domains, a single blotting item, and a single overall oiliness item.
The 6 item OSIS includes Annoyance (3 items) and Self-Concept
(3 items) domains. Conﬁrmatory factor analysis provided
support for the construct validity of the ﬁnal item-scale struc-
tures. The OSSAS and OSIS scales had acceptable item conver-
gent validity (item-scale correlations >0.40) and ﬂoor and ceiling
effects (<20%). Cronbach’s alpha coefﬁcients ranged from 0.83–
0.89 for the OSSAS and 0.82–0.87 for the OSIS, demonstrating
excellent internal consistency. The a priori criterion for test-retest
reliability (ICC  0.7) was met for one of the three OSSAS
domains and one of the two OSIS domains. Correlations of the
Skindex-29 and Acne-QoL scales with the OSSAS (range: -0.08–
0.38) and OSIS (range: 0.37–0.73) domain scores met content
expectations for these scales. OSSAS and OSIS domains distin-
guished among groups of patients who differed in terms of both
patient reported facial OS severity (p < 0.0001) and patient
reported bother associated with OS (p < 0.0001). CONCLU-
SION: The OSSAS and OSIS provide valid self-report measures
of facial OS severity and the emotional impact of OS, respec-
tively. Test-retest reliability and responsiveness of these measures
require further evaluation.
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OBJECTIVES: Varenicline (Champix®) is a new drug indicated
for smoking cessation. The objective was to analyse the efﬁciency
of varenicline compared with bupropion, NRT (nicotine replace-
ment therapy) and no pharmacological treatment in Spain.
METHODS: A Markov model was developed to analyse the
Abstracts A471
